Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA Approves Abbott Laboratories's Device For Leaking Heart Valve-Reuters


Friday, 25 Oct 2013 12:33pm EDT 

Reuters reported that the U.S. Food and Drug Administration has approved Abbott Laboratories's MitraClip medical device, used to stop heart valve leakage in patients deemed unable to endure valve repair through open heart surgery, the Company said on October 25, 2013. The MitraClip treats mitral regurgitation, a condition in which the mitral valve of the heart does not close properly, causing blood leakage that can lead to stroke, heart attack or even death. It has estimated the disorder affects about one in 10 people aged 75 and older.